Research graph
References from 18F-FDG Is a Surrogate Marker of Therapy Response and Tumor Recovery after Drug Withdrawal during Treatment with a Dual PI3K/mTOR Inhibitor in a Preclinical Model of Cisplatin-Resistant Ovarian Cancer. Local targets link to admitted publications; unresolved targets remain external evidence.
Cancer statistics, 2012
2012 · External reference
Phase II evaluation of pemetrexed in the treatment of recurrent or persistent platinum-resistant ovarian or primary peritoneal carcinoma: a study of the Gynecologic Oncology Group
10.1200/jco.2008.19.2963 · 2009 · External reference
Relationship among surgical complexity, short-term morbidity, and overall survival in primary surgery for advanced ovarian cancer
10.1016/j.ajog.2007.10.495 · 2007 · External reference
Relapsed ovarian cancer: challenges and management strategies for a chronic disease
10.1634/theoncologist.7-suppl_5-20 · 2002 · External reference
Recurrent epithelial ovarian carcinoma: a randomized phase III study of pegylated liposomal doxorubicin versus topotecan
10.1200/jco.2001.19.14.3312 · 2001 · External reference
Randomized phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in patients with platinum-resistant ovarian cancer
10.1200/jco.2006.09.6735 · 2007 · External reference
Biologic rationale and clinical activity of mTOR inhibitors in gynecological cancer
10.1016/j.ctrv.2012.02.001 · 2012 · External reference
Integrated genomic analyses of ovarian carcinoma
10.1038/nature10166 · 2011 · External reference
AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth
10.1038/sj.onc.1207721 · 2004 · External reference
PI3K/AKT/mTOR inhibitors in ovarian cancer
10.2174/092986710794182999 · 2010 · External reference
Identification and characterization of NVP-BEZ235, a new orally available dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor with potent in vivo antitumor activity
10.1158/1535-7163.mct-08-0017 · 2008 · External reference
Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma
10.1158/1078-0432.ccr-10-2289 · 2011 · External reference
Inhibition of phosphatidylinositol 3′-kinase increases efficacy of paclitaxel in in vitro and in vivo ovarian cancer models
2002 · External reference
Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma
10.1016/j.humpath.2012.03.011 · 2012 · External reference
Evaluation of 2-deoxy-2-[18F]fluoro-d-glucose- and 3′-deoxy-3′-[18F]fluorothymidine-positron emission tomography as biomarkers of therapy response in platinum-resistant ovarian cancer
10.1007/s11307-012-0554-2 · 2012 · External reference
FDG uptake is a surrogate marker for defining the optimal biological dose of the mTOR inhibitor everolimus in vivo
10.1038/sj.bjc.6605076 · 2009 · External reference
Management strategies for recurrent platinum-resistant ovarian cancer
10.2165/11591720-000000000-00000 · 2011 · External reference
Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer
10.1097/cco.0b013e3283564230 · 2012 · External reference
[18F]fluorodeoxyglucose positron emission tomography correlates with Akt pathway activity but is not predictive of clinical outcome during mTOR inhibitor therapy
10.1200/jco.2008.18.8383 · 2009 · External reference
10.1593/tlo.11118 · 2011 · Admitted local publication
Monitoring predominantly cytostatic treatment response with 18F-FDG PET
10.2967/jnumed.108.057273 · 2009 · External reference
Characterization of Rictor phosphorylation sites reveals direct regulation of mTOR complex 2 by S6K1
10.1128/mcb.00735-09 · 2009 · External reference
mTORC1-activated S6K1 phosphorylates Rictor on threonine 1135 and regulates mTORC2 signaling
10.1128/mcb.00601-09 · 2010 · External reference
10.1016/j.ygyno.2009.04.012
10.1016/j.ygyno.2009.04.012 · 2009 · External reference
Dose-dense chemotherapy improves mechanisms of antitumor immune response
10.1158/0008-5472.can-12-2225 · 2012 · External reference
The combination of monthly carboplatin and weekly paclitaxel is highly active for the treatment of recurrent ovarian cancer
10.1016/j.ygyno.2009.08.021 · 2009 · External reference
Pharmacokinetics and tissue distribution of intraperitoneal paclitaxel with different carrier solutions
10.1007/s00280-003-0680-2 · 2003 · External reference
In vitro studies of Taxol as a radiation sensitizer in human tumor cells
10.1093/jnci/86.6.441 · 1994 · External reference
Reversal of the multidrug resistance phenotype with cremophor EL, a common vehicle for water-insoluble vitamins and drugs
1990 · External reference
Cremophor EL inhibits 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced protein phosphorylation in human myeloblastic leukemia ML-1 cells
1991 · External reference
Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study
10.1182/blood-2008-12-196543 · 2009 · External reference
Patient and plan characteristics affecting abandonment of oral oncolytic prescriptions
2011 · External reference
Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib
10.1200/jco.2009.26.3087 · 2010 · External reference
FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0
10.1007/s00259-009-1297-4 · 2010 · External reference
Procedure guideline for tumor imaging with 18F-FDG PET/CT 1.0
2006 · External reference
Compliance with PET acquisition protocols for therapeutic monitoring of erlotinib therapy in an international trial for patients with non-small cell lung cancer
10.1007/s00259-010-1665-0 · 2011 · External reference
